BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Approval

Eisai And Henlius Sign Exclusive Japan Commercialisation Deal For Anti PD 1 Antibody Serplulimab

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO:&nbs...

February 10, 2026 | News

Aucta Pharmaceuticals Launches PYQUVI Oral Suspension For Duchenne Muscular Dystrophy In The US

Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated f...

February 10, 2026 | News

Kelun Biotech Wins China Approval For Sacituzumab Tirumotecan In Advanced Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-dir...

February 09, 2026 | News

Australian World First Paediatric mRNA Brain Cancer Trial Signals Expansion Opportunity For Canada And The United States

Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. -- Providence Ther...

February 06, 2026 | News

Everest Medicines Secures Exclusive Asia Pacific Rights To First In Class Dual Target SHPT Therapy MT1013

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturi...

February 06, 2026 | News

Biosion Doses First Patient In Phase 1 Trial Of Novel Anti SIRPα Antibody BSI 082

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In...

February 05, 2026 | News

Insilico Medicine Receives $5 Million Milestone From Menarini Group After First Patient Dosed In Phase 1 Trial Of AI Designed Cancer Therapy

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone paymen...

February 05, 2026 | News

SanegeneBio Licenses RNAi Programme To Genentech In Global Deal Valued Up To USD 1.7 Billion

SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million up...

February 04, 2026 | News

Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label ...

February 03, 2026 | News

MicuRx Pharmaceuticals Receives FDA IND Clearance For MRX 5 In Mycobacterium abscessus Pulmonary Disease

MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant...

February 03, 2026 | News

Closing Asia’s Cancer Evidence Gap Through Translational Science And Policy Leadership

In this BioPharma APAC interview, Dr Yun Yen, Program Committee Chair for the 2026 ASCO Breakthrough meeting, shares a candid translational...

February 02, 2026 | Expert Insight

Insilico Medicine Partners With Qilu Pharmaceutical Group To Advance AI Driven Cardiometabolic Drug Discovery

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceuti...

January 29, 2026 | News

Hanmi Pharmaceutical Advances Global GLP 1 Strategy With Mexico Distribution Agreement For Efpeglenatide

Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease ...

January 29, 2026 | News

Nuance Pharma’s Ohtuvayre NDA Accepted For Review In China For COPD Maintenance Treatment

Nuance Pharma announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA)...

January 28, 2026 | News

Stay Connected